Ajeeth Narayan (@ajeeth_narayan) 's Twitter Profile
Ajeeth Narayan

@ajeeth_narayan

ID: 857628480741265408

calendar_today27-04-2017 16:12:18

11 Tweet

8 Followers

11 Following

Investec (@investec) 's Twitter Profile Photo

Deal or no deal? Listen to our UK chief economist on the outlook for business after Brexit. #podcast #Brexit #trade #business

Darshan Mehta (@darshanvmehta1) 's Twitter Profile Photo

Investec on Dr Reddys.....Must say that i am really impressed lately with the pharma coverage by Investec....Their analysis has been really good Anshuman Gupta

Investec on Dr Reddys.....Must say that i am really impressed lately with the pharma coverage by Investec....Their analysis has been really good <a href="/anshumang1002/">Anshuman Gupta</a>
Investec_India (@investecindia) 's Twitter Profile Photo

#GSKCH reported strong 1Q revenue growth of 12% yoy (led by 13% volume growth) and EBITDA growth 38% yoy (GM expansion). The company reiterated its focus on (1) High-science (premium) products – Growth+, Protein+ and Boost RTD and (2) penetration, led by LUPs (high-teens growth).

Investec_India (@investecindia) 's Twitter Profile Photo

#Eicher’s Q1 EBITDA was in-line with our est., margin resilience vs. pressure seen in peers highlights RE’s distinctive positioning. Strong demand outlook, favourable product mix and expansion in tier 2 states should help RE continue to outperform the industry, in our view.

Investec_India (@investecindia) 's Twitter Profile Photo

#SunTV reported strong 1Q rev growth, led by IPL franchise (Rs2.2bn EBIT vs our expectation of Rs1bn). Declining shares across key markets (Tamil/Telugu) is deal breaker for us. Factoring in IPL gains in FY19E and beyond, we increase estimates 2-3%

Investec_India (@investecindia) 's Twitter Profile Photo

#Lupin Mgmt guidance for recovery in 2H/FY20 is sensitive to the success of a few large products, making earnings susceptible to further downgrades. Our FY19E/ 20E EPS cuts post 1QFY19’s big miss (33% PBT miss) assumes most +ves in-line with mgmt. guidance

Investec_India (@investecindia) 's Twitter Profile Photo

India #Pharma #Cadila pipeline execution has been good, lot more is expected. 1QFY19 nos missed est. More competition in Lialda / Asacol HD and delay in key prods remain key risks to earnings.

Investec_India (@investecindia) 's Twitter Profile Photo

#Redington India: Overblown Turkish concerns - 8% of its revenues & 2% of consolidated PAT derived from Turkish biz in FY18. Sharp depreciation in Lira vs USD led to worries on potential impact on its earnings- quite unreasonable in our view. Multiple positive catalysts ahead